Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2019 Apr 10;33:2058738419839592. doi: 10.1177/2058738419839592

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — CD8⁺ T cells, but not PD-1 expressing CD4⁺ and CD8⁺ T cells, were significantly decreased in the peripheral blood from patients with NSCLC after two cycles of chemotherapy. PBMCs were collected from peripheral blood samples of 20 healthy donors and from 50 patients with NSCLC before and after chemotherapy: (a) Representative staining patterns of PD-1⁺ on CD8⁺ T cells (CD3⁺ gated) of one healthy donor and one patient before and after two cycles of chemotherapy. (b, c) The absolute number (b) and frequency (c) of CD3⁺CD8⁺ T cells in the peripheral blood of healthy donors and patients with NSCLC before and after chemotherapy. (d, f) Frequencies of PD-1-expressing CD3⁺CD8⁺ (d) and CD3⁺CD4⁺ (f) T cells in peripheral blood of healthy donors and patients with NSCLC before and after chemotherapy. (e, g) Representing the impact of chemotherapy on the frequencies of PD-1⁺CD8⁺ (e) and PD-1⁺CD4⁺ (g) T cells in peripheral blood of patients with NSCLC. HD: healthy donor; CT: chemotherapy.